Umoja Biopharma
In vivo lentiviral vector platform for manufacturing CAR-T cells directly inside patients
- Sector
- Biotech
- Founded
- 2019
- Latest Form D
- $210M, Jun 2021
- Total capital
- $210M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $210M
- 1 Form D · last Jun 2021
- 64 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 39 pending · first 2025
- Rank in peer group#73 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$210M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#73 · top 21%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrew M. ScharenbergExecutive Officer, DirectorNamed in SEC Form D filings
- Andrew M. ScharenbergExecutive Officer, DirectorNamed in SEC Form D filings
- Anna FrenchDirectorNamed in SEC Form D filings
- Irena MelnikovaExecutive OfficerNamed in SEC Form D filings
- John HamerDirectorNamed in SEC Form D filings
- Luke EvninDirectorNamed in SEC Form D filings
Show all 9 people
- Philip S. LowDirectorNamed in SEC Form D filings
- Philip S. LowDirectorNamed in SEC Form D filings
- Robert GlassmanDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 40- PendingParticles Displaying Adhesion-molecule FusionsUSPTOApplication 19126455
- PendingLentiviral Particles Displaying Fusion Molecules And Uses ThereofUSPTOApplication 19126453
- PendingDifferentiation Of Stem Cells In Suspension CultureUSPTOApplication 18995112
Show all 40 patent records
- Particles Displaying Adhesion-molecule FusionsJun 25, 2026 · Application 19126455Pending
- Lentiviral Particles Displaying Fusion Molecules And Uses ThereofJun 18, 2026 · Application 19126453Pending
- Differentiation Of Stem Cells In Suspension CultureJan 29, 2026 · Application 18995112Pending
- Manufacturing Viral ParticlesDec 18, 2025 · Application 18866424Pending
- Engineered Stem Cells And Uses ThereofDec 4, 2025 · Application 18873311Pending
- Compositions And Methods For Nk Cell DifferentiationNov 20, 2025 · Application 18872801Pending
- Viral Vectors And Packaging Cell LinesApr 17, 2025 · Application 18991176Pending
- Viral Vectors And Packaging Cell LinesApr 17, 2025 · Application 18991101Pending
- Viral Particle With Surface Stimulating MoleculesFeb 13, 2025 · Application 18931597Pending
- Cytotoxic Innate Lymphoid Cell And Uses ThereofFeb 6, 2025 · Application 18720599Pending
- Viral Vectors And Packaging Cell LinesFeb 4, 2025 · US 12,215,337Granted
- Lentivirus For Generating Cells Expressing ANTI-CD19 Chimeric Antigen ReceptorMay 2, 2024 · Application 18262859Pending
- Retroviral Vector For Universal Receptor TherapyApr 18, 2024 · Application 17766654Pending
- Vector System For Delivery Of Multiple Polynucleotides And Uses ThereofDec 21, 2023 · Application 18037986Pending
- Bispecific Transduction EnhancerNov 2, 2023 · Application 17796523Pending
- Gated Adapter Targeting ReceptorAug 31, 2023 · Application 18016307Pending
- Multicistronic Vector For Surface Engineering Lentiviral ParticlesJan 20, 2022 · Application 17295599Pending
- CD58-PSEUDOTYPED Viral Particles And Uses ThereofApplication 63736439Pending
- Improved Rapamycin Activated Synthetic Receptor Transgene ConstructsApplication PCTUS2025061054Pending
- Multispecific Immune Cell Engager And Uses ThereofApplication PCTUS2025028138Pending
- Viral Particle With Surface Stimulating MoleculesApplication 63339332Pending
- Lentiviral Delivery Of ANTI-CD20 Chimeric Antigen ReceptorsApplication PCTUS2024027211Pending
- Multispecific Immune Cell Engager And Uses ThereofApplication 63644329Pending
- Fusion Protein For Use As Immune Cell EngagerApplication PCTUS2025028136Pending
- Cytokine Armored Engineered Innate Lymphoid Cells And Related MethodsApplication PCTUS2025058482Pending
- Polynucleotide Construct For Chimeric Antigen Receptor Expression And Related Viral Vectors And MethodsApplication PCTUS2025061039Pending
- Fusion Protein For Use As Immune Cell EngagerApplication 63644321Pending
- Polynucleotide Construct And Related Viral Vectors And MethodsApplication 19126176Pending
- Polynucleotide Construct For Chimeric Antigen Receptor Expression And Related Viral Vectors And MethodsApplication 63738507Pending
- Rapamycin Activated Synthetic Receptor Transgene ConstructsApplication 63738510Pending
- Lentiviral Delivery Of ANTI-CD22 Chimeric Antigen ReceptorsApplication PCTUS2025022794Pending
- Cytokine Armored Engineered Innate Lymphoid Cells And Related MethodsApplication 63729310Pending
- Manufacturing Viral ParticlesApplication PCTUS2025027162Pending
- Differentiation Of Stem Cells In Suspension CultureApplication PCTUS2023071097Pending
- Particles Displaying Adhesion-molecule FusionsApplication 63579188Pending
- Lentiviral Particles Displaying Fusion Molecules And Uses ThereofApplication PCTUS2023078732Pending
- Lineage-loci Engineered Cell Therapy And Related Methods Of Producing And Using SameApplication 63729312Pending
- Particles Displaying Adhesion-molecule FusionsApplication PCTUS2023078688Pending
- Polynucleotide Construct And Related Viral Vectors And MethodsApplication PCTUS2023078748Pending
- Engineered Induced Stem Cell Derived Myeloid Cells And Methods Of Differentiating And Using SameApplication 63609821Pending
Related companies, and why
- Gila Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- SANARENTERO LLCSimilar federal contract value in Biotech · null in contracts
- KARYOPHARM THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- ADARx PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- COARE HOLDINGS INCSimilar federal contract value in Biotech · null in contracts
- Reservoir Neuroscience, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .